ライブ

BioPharma DiveArvinas, Pfizer find new partner for ‘Protac’ breast cancer drug FierceBiotechAlphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model Endpoints NewsFive burning Qs for Isomorphic Labs after $2.1B raise for AI biotech Lonza NewsLonza Launches Xcite AAV Producer Cell Line Platform - Contract Pharma Endpoints NewsPfizer and Arvinas give disappointing breast cancer drug to Rigel FierceBiotechBoehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset Endpoints NewsBayer to make 'careful but aggressive' return to pharma M&A, CEO says Endpoints NewsAlkermes' narcolepsy Phase 3 success; Boehringer's antibody deal FierceBiotechAstraZeneca’s $800M bet undermined by immunogenicity in phase 3 10x Genomics NewsA Look At 10x Genomics (TXG) Valuation After A Strong Year And Recent Share Price Pullback - Yahoo Finance PharmaVoiceHow tough is it getting for vaccine makers in the U.S.?FDA News ReleasesFDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

Endpoints News 2026年5月12日

Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal

Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug L...

Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcolepsy, hit its primary ...